Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Hearing Disorders: HELP
Articles by Daniel Stark
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, D. Stark wrote the following 2 articles about Hearing Disorders.
 
+ Citations + Abstracts
1 Review Patient-Reported Measures of Hearing Loss and Tinnitus in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review. 2016

Stark, Daniel / Rosenberg, Abby R / Johnston, Donna / Knight, Kristin / Caperon, Lizzie / Uleryk, Elizabeth / Frazier, A Lindsay / Sung, Lillian. ·Section of Oncology and Cancer Research, Leeds Institute of Molecular Medicine, University of Leeds, United Kingdom. · Hematology/Oncology, Seattle Children's Hospital, WA. · Division of Paediatric Haematology/Oncology, Children's Hospital of Eastern Ontario, Ottawa, Canada. · Pediatric Audiology, Oregon Health and Science University, Portland. · Scholarly Communications and Researcher Skills, University of Leeds, United Kingdom. · E. M. Uleryk Consulting, Toronto, Ontario, Canada. · Dana-Farber/Boston Children's Cancer Center, MA. · Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. ·J Speech Lang Hear Res · Pubmed #27603148.

ABSTRACT: Purpose: We identified studies that described use of any patient-reported outcome scale for hearing loss or tinnitus among children and adolescents and young adults (AYAs) with cancer or hematopoietic stem cell transplantation (HSCT) recipients. Method: In this systematic review, we performed electronic searches of OvidSP MEDLINE, EMBASE, and PsycINFO to August 2015. We included studies if they used any patient-reported scale of hearing loss or tinnitus among children and AYAs with cancer or HSCT recipients. Only English language publications were included. Two reviewers identified studies and abstracted data. Results: There were 953 studies screened; 6 met eligibility criteria. All studies administered hearing patient-reported outcomes only once, after therapy completion. None of the studies described the psychometric properties of the hearing-specific component. Three instruments (among 6 studies) were used: Health Utilities Index (Barr et al., 2000; Fu et al., 2006; Kennedy et al., 2014), Hearing Measurement Scales (Einar-Jon et al., 2011; Einarsson et al., 2011), and the Tinnitus Questionnaire for Auditory Brainstem Implant (Soussi & Otto, 1994). All had limitations, precluding routine use for hearing assessment in this population. Conclusions: We identified few studies that included hearing patient-reported measures for children and AYA cancer and HSCT patients. None are ideal to take forward into future studies. Future work should focus on the creation of a new psychometrically sound instrument for hearing outcomes in this population.

2 Clinical Trial Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour. 2011

Rimmer, Y / Chester, J / Joffe, J / Stark, D / Shamash, J / Powles, T / White, J / Wason, J / Parashar, D / Armstrong, G / Mazhar, D / Williams, M V. ·Oncology Centre, Box 193, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Hills Road, Cambridge CB2 0QQ, UK. ·Br J Cancer · Pubmed #21847130.

ABSTRACT: BACKGROUND: We used bleomycin, etoposide, cisplatin (BEP), the most effective regimen in the treatment of germ cell tumours (GCTs) and increased dose-density by using pegfilgrastim to shorten cycle length. Our aim was to assess safety and tolerability. METHODS: Sixteen male patients with intermediate or poor prognosis metastatic GCT were treated with four cycles of 3-day BEP with G-CSF on a 14-day cycle for a planned relative dose-density of 1.5 compared with standard BEP. RESULTS: Eleven intermediate and five poor prognosis patients were treated. In all, 14 of 16 patients completed the study treatment. Toxicities were comparable to previous studies using standard BEP, except for mucositis and haematological toxicity that were more severe. The overall relative dose-density for all 16 patients was mean 1.38 (range 0.72-1.5; median 1.46). Complete response was achieved after chemotherapy alone in two patients (13%) and following chemotherapy plus surgery in nine additional patients (56%). Four patients (25%) had a partial response and normalised their marker levels. At a median follow-up of 4.4 years (range 2.1-6.8) the estimated 5-year progression-free survival probability is 81% (95% CI 64-100%). CONCLUSION: Accelerated BEP is tolerable without major additional toxicity. A randomised controlled trial will be required to obtain comparative efficacy data.